title: Safety and efficacy of a bolus injection of landiolol hydrochloride as a premedication for multidetector-row computed tomography coronary angiography.
abstract: BACKGROUND
  We evaluated the safety and efficacy of a bolus injection of landiolol hydrochloride, an ultrashort-acting β1-selective antagonist, as an additional treatment after premedication with an oral β-blocker to reduce heart rate prior to multidetector-row computed tomography (MDCT) coronary angiography (CAG).
  
  
  RESULTS
  A total of 458 patients who underwent MDCT CAG were retrospectively enrolled. Image quality and hemodynamic parameters were compared in patients before and after approval of landiolol hydrochloride. If heart rate reduction was insufficient after premedication with an oral β-blocker, a bolus injection of landiolol hydrochloride (n=66) or other drugs (n=30) was used. The percentage of evaluable images per segment in patients after approval of landiolol (99.3%) was greater than that in patients before approval of landiolol (97.4%, P<0.01). Heart rates before scanning in patients receiving landiolol hydrochloride were similar to those receiving other drugs. Heart rate was significantly reduced approximately 5 min after injection of landiolol hydrochloride and increased shortly. No decrease in systolic blood pressure or other adverse effects was observed.
  
  
  CONCLUSIONS
  Bolus injection of landiolol hydrochloride sufficiently reduced heart rate without significantly reducing systolic blood pressure and produced a high percentage of evaluable images, suggesting that bolus injection of landiolol hydrochloride as an additional pretreatment is feasible in MDCT CAG.
authors.affiliation: Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Osawa
authors.forename: Toru
authors.initials: T
authors.lastname: Miyoshi
authors.forename: Shuhei
authors.initials: S
authors.lastname: Sato
authors.forename: Noriaki
authors.initials: N
authors.lastname: Akagi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Morimitsu
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Nakamura
authors.forename: Kunihisa
authors.initials: K
authors.lastname: Kohno
authors.forename: Kengo
authors.initials: K
authors.lastname: Kusano
authors.forename: Susumu
authors.initials: S
authors.lastname: Kanazawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ito
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D000368:Aged; D000369:Aged, 80 and over; D017023:Coronary Angiography / Q000379:methods*; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects / Q000494:pharmacology*; D061330:Multidetector Computed Tomography / Q000379:methods*; D012189:Retrospective Studies; D013997:Time Factors; D014508:Urea / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000319:Adrenergic beta-Antagonists; D009025:Morpholines; C077049:landiolol; D014508:Urea